Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN67,2967,332,60
Msft-0,47
Nokia3,483,52951,94
IBM1,48
Mercedes-Benz Group AG64,8464,861,38
PFE2,24
25.06.2024 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 24.06.2024
UCB SA (UCB.BR, Brussels)
Závěr k 24.6.2024 Změna (%) Změna (EUR) Objem obchodů (EUR)
138,85 -0,18 -0,25 47 185 784
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 25.06.2024
Popis společnosti
Obecné informace
Název společnostiUCB SA
TickerUCB
Kmenové akcie:Ordinary Shares
RICUCB.BR
ISINBE0003739530
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 9 083
Akcie v oběhu k 31.12.2023 189 750 583
MěnaEUR
Kontaktní informace
UliceAllee de la Recherche, 60
MěstoANDERLECHT
PSČ1070
ZeměBelgium
Kontatní osobaAntje Witte
Funkce kontaktní osobyHead of Investor Relations
Telefon3 225 599 999
Fax3225599900
Kontatní telefon3 255 599 414

Business Summary: Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, UCB SA revenues decreased 5% to EUR5.25B. Net income before extraordinary items decreased 18% to EUR343M. Revenues reflect Vimpat segment decrease of 65% to EUR394M, Other Products segment decrease of 53% to EUR153M, USA segment decrease of 15% to EUR2.45B, Japan segment decrease of 17% to EUR269M. Net income also reflects Marketing/Selling Expenses increase of 7% to EUR1.59B (expense).
Odvětvová klasifikace
TRBC2012Biopharmaceuticals
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 25.06.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Executive Director, Member of the Executive CommitteeJean-Christophe Tellier6528.04.202201.07.2011
Chief Financial Officer, Executive Vice President, Member of the Executive CommitteeSandrine Dufour5801.07.202001.07.2020
Executive Vice President, Chief Human Resource Officer, Member of the Executive CommitteeJean-Luc Fleurial5901.01.2017
Executive Vice President, Chief Scientific Officer, Member of the Executive CommitteeDhavalkumar Patel63
Executive Vice President, General Counsel, Member of the Executive CommitteeDenelle Waynick Johnson57
Executive Vice President Immunology Solutions & Head of US, Member of the Executive CommitteeEmmanuel Caeymaex55
Executive Vice President, Chief Medical Officer, Member of the Executive BoardIris Loew-Friedrich64
Executive Vice President, Supply and Technology Solutions, Member of the Executive CommitteeKirsten Lund-jurgensen6501.01.2019
Group Secretary GeneralXavier Michel-